<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00720668</url>
  </required_header>
  <id_info>
    <org_study_id>RFA006</org_study_id>
    <nct_id>NCT00720668</nct_id>
  </id_info>
  <brief_title>The Risk of Exacerbation of Chronic Hepatitis B After Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma</brief_title>
  <acronym>HBV-HCC</acronym>
  <official_title>The Risk of Exacerbation of Chronic Hepatitis B After Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aim to find out the risk of exacerbation of chronic hepatitis B after percutaneous
      radiofrequency ablation (RFA) or hepatectomy for HCC, and it's effect to treatment outcome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It has been reported that HBV replication can be reacted after chemotherapy or immunotherapy,
      which will lead to exacerbation of chronic hepatitis B (ECHB). It is still unknown that if
      percutaneous radiofrequency ablation or liver resection for hepatocellular carcinoma (HCC)
      will react the replication of HBV or not. This study aim to find out the risk of exacerbation
      of chronic hepatitis B after percutaneous radiofrequency ablation (RFA) or hepatectomy for
      HCC, and it's effect to treatment outcome.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2006</start_date>
  <completion_date type="Anticipated">May 2010</completion_date>
  <primary_completion_date type="Anticipated">March 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The Rate of Exacerbation of chronic hepatitis B after RFA</measure>
    <time_frame>one week, one month, one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>survival</measure>
    <time_frame>1, 3, 5-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>one month</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hepatitis B</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>patient with hepatocellular carcinoma after radiofrequency ablation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radiofrequency ablation</intervention_name>
    <description>radiofrequency ablation for HCC</description>
    <arm_group_label>1</arm_group_label>
    <other_name>RFA</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with hepatocellular carcinoma (HCC) after percutaneous radiofrequency ablation.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 - 75 years

          -  HBV carrier with HCC

          -  After percutaneous radiofrequency ablation;

          -  No history of encephalopathy, ascites refractory to diuretics or variceal bleeding

          -  No HCV or HIV co-infection

          -  No previous treatment of HCC

          -  No previous treatment of HBV except Lamivudine

        Exclusion Criteria:

          -  Patient compliance is poor

          -  Active clinically serious infections ( &gt; grade 2 National Cancer Institute
             [NCI]-Common Terminology Criteria for Adverse Events [CTCAE] version 3.0)

          -  Known history of human immunodeficiency virus (HIV) infection

          -  Known Central Nervous System tumors including metastatic brain disease

          -  Patients with clinically significant gastrointestinal bleeding within 30 days prior to
             study entry

          -  Distantly extrahepatic metastasis

          -  History of organ allograft

          -  Substance abuse, medical, psychological or social conditions that may interfere with
             the patient's participation in the study or evaluation of the study results

          -  Excluded therapies and medications, previous and concomitant

          -  Prior use of any systemic anti-cancer treatment for HCC, eg. chemotherapy,
             immunotherapy or hormonal therapy (except that hormonal therapy for supportive care is
             permitted). Antiviral treatment is allowed, however interferon therapy must be stopped
             at least 4 weeks prior randomization

          -  Prior use of systemic investigational agents for HCC

          -  Autologous bone marrow transplant or stem cell rescue within four months of start of
             study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>min-shan chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Hepatobilliary Surgery, Cancer Center, Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>min-shan chen, MD</last_name>
    <phone>86-20-87343117</phone>
    <phone_ext>86-20-87343117</phone_ext>
    <email>Chminsh@mail.sysu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Center, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min-Shan Chen, MD</last_name>
      <phone>86-20-87343117</phone>
      <phone_ext>86-20-87343117</phone_ext>
      <email>Chminsh@mail.sysu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Min-Shan Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yao-Jun Zhang, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005 Nov;42(5):1208-36.</citation>
    <PMID>16250051</PMID>
  </results_reference>
  <results_reference>
    <citation>Poon RT, Fan ST, Tsang FH, Wong J. Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective. Ann Surg. 2002 Apr;235(4):466-86. Review.</citation>
    <PMID>11923602</PMID>
  </results_reference>
  <results_reference>
    <citation>Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, Lin XJ, Lau WY. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006 Mar;243(3):321-8.</citation>
    <PMID>16495695</PMID>
  </results_reference>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2008</study_first_submitted>
  <study_first_submitted_qc>July 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2008</study_first_posted>
  <last_update_submitted>February 6, 2009</last_update_submitted>
  <last_update_submitted_qc>February 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2009</last_update_posted>
  <responsible_party>
    <name_title>minshan chen</name_title>
    <organization>cancer canter, Sun Yat-sen University</organization>
  </responsible_party>
  <keyword>hepatitis B</keyword>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>radiofrequency ablation</keyword>
  <keyword>reactivation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

